Compare
Invivyd, Inc. vs Protalix BioTherapeutics, Inc. vs Champions Oncology, Inc. vs Fennec Pharmaceuticals Inc.
| Latest fiscal year | Invivyd, Inc. IVVD | Protalix BioTherapeutics, Inc. PLX | Champions Oncology, Inc. CSBR | Fennec Pharmaceuticals Inc. FENC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-04-30 | 2025-12-31 |
| Revenue | $53.43M | $52.74M | $59.42M | $44.64M |
| Revenue growth (YoY) | +110.5% | -1.2% | +4.4% | -6.1% |
| Gross margin | n/a | 48.8% (computed) | 48.0% (computed) | n/a |
| Operating margin | -104.0% | -10.4% | -1.9% | -14.1% |
| Net margin | -98.2% | -12.5% | -2.0% | -21.8% |
| Net income | -$52.49M | -$6.60M | -$1.18M | -$9.74M |
| EPS (Diluted) | -$0.30 | -$0.08 | -$0.08 | -$0.34 |
| Operating cash flow | -$58.13M | -$11.99M | -$4.47M | -$12.47M |
| Free cash flow | -$58.29M | -$13.63M | -$5.04M | n/a |
| Cash & equivalents | $226.69M | $14.68M | n/a | $36.79M |
| Total assets | $276.88M | $82.35M | $26.99M | $70.55M |
| Total liabilities | $35.34M | $34.12M | $22.92M | $35.08M |
| Shareholders' equity | $241.54M | $48.23M | $3.94M | $35.47M |
| Return on year-end equity | -21.7% | -13.7% | -29.8% | -27.5% |
| Shares outstanding | 281.99M | 80.43M | 13.89M | 34.16M |
Revenue, most recent five fiscal years
| Fiscal year | Invivyd, Inc. | Protalix BioTherapeutics, Inc. | Champions Oncology, Inc. | Fennec Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $53.43M Ended 2025-12-31 | $52.74M Ended 2025-12-31 | $59.42M Ended 2026-04-30 | $44.64M Ended 2025-12-31 |
| 1 year earlier | $25.38M Ended 2024-12-31 | $53.40M Ended 2024-12-31 | $56.94M Ended 2025-04-30 | $47.54M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $65.49M Ended 2023-12-31 | $50.16M Ended 2024-04-30 | $21.25M Ended 2023-12-31 |
| 3 years earlier | n/a | $47.64M Ended 2022-12-31 | $53.87M Ended 2023-04-30 | $1.53M Ended 2022-12-31 |
| 4 years earlier | n/a | $38.35M Ended 2021-12-31 | $49.11M Ended 2022-04-30 | n/a |